A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

PHASE2TerminatedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

June 23, 2020

Study Completion Date

August 19, 2020

Conditions
Respiratory Tract Infection
Interventions
BIOLOGICAL

Formulation A

RSV vaccine

BIOLOGICAL

Formulation B

Adjuvanted RSV vaccine

BIOLOGICAL

Formulation C

RSV vaccine

BIOLOGICAL

Placebo

Placebo

Trial Locations (16)

2010

Holdsworth House Medical Practice, Sydney

2035

Australian Clinical Research Network, Maroubra

2145

Westmead Hospital (Infectious Diseases and Microbiology), Westmead

2291

AIM Centre (Hunter Diabetes Centre), Merewether

3079

Doctors of Ivanhoe, Ivanhoe

3124

Emeritus Research Pty. Ltd., Camberwell

3128

Eastern Health, Box Hill

3168

Monash Medical Centre, Clayton

3220

Barwon Health, Geelong

4068

Data Health Australia Pty Limited (Trading as AusTrials), Taringa

6009

Institute for Respiratory Health, Nedlands

6163

TrialsWest, Spearwood

33143

Qps Mra, Llc, South Miami

61614

Optimal Research, LLC, Peoria

68025

Synexus Clinical Research US, Fremont

68114

Quality Clinical Research, Inc., Omaha

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03572062 - A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults | Biotech Hunter | Biotech Hunter